RxDoctor Payments Data

Charles Hall, MD

Pulmonary Disease · Bay Shore, NYNPI 1386637163

Payments from drug & device makers

$329in general payments, 2019–2025

Across 8 payments — averaging $41.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$220
  • Genentech USA, Inc.$40
  • Mylan Specialty L.p.$23
  • United Therapeutics Corporation$18
  • Sunovion Pharmaceuticals Inc.$15
  • Merck$13

What the payments were for

  • Food & beverage$25879%
  • Education$7021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$329 in reported general payments places this provider in the 35th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$313,840
Medicare patients
956
Services billed
3,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter291$416,719
XolairOmalizumab57$225,929
Breo ElliptaFluticasone/Vilanterol221$216,426
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr145$163,478
Dupixent SyringeDupilumab29$109,086
Pirfenidone26$96,836
Spiriva RespimatTiotropium Bromide49$59,092
Incruse ElliptaUmeclidinium Bromide65$48,082
Arnuity ElliptaFluticasone Furoate89$40,895
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$29,667
Albuterol Sulfate HfaAlbuterol Sulfate543$27,904
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$25,148
Spiriva HandihalerTiotropium Bromide25$24,521
Fluticasone-SalmeterolFluticasone Propion/Salmeterol112$24,017
SymbicortBudesonide/Formoterol Fumarate39$22,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckDulera$13$15,28716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Bay Shore

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →